tbuckley/cabot-search huggingface dataset:
Haemoglobin decline before coeliac disease diagnosis: a nationwide transfusion cohort study of 1.1 million blood donors
Authors: Jonas F Ludvigsson, Arvid Sjölander, Joseph A Murray, Henrik Hjalgrim, Gustaf Edgren
Journal: Gut (2017)

The recent British Society of Gastroenterology guidelines for the management and diagnosis of coeliac disease (CD) suggests that individuals with iron-deficiency anaemia be tested for CD.1 We have previously shown that decreasing haemoglobin (Hb) levels precede diagnosis of a number of malignancies, including most GI and haematological malignancies.2 If Hb levels begin to decline prior to CD diagnosis, this may provide a means to estimate the duration from disease onset to diagnosis.

We therefore set up a case-control study to examine Hb concentration before CD diagnosis using a similar approach as in a previous study.2 We first linked data on Hb concentration measured repeatedly for 1.1 million blood donors in the Swedish portion of the Scandinavian Donations and Transfusions database 2,3 with a nationwide histopathology database providing diagnosis of villous atrophy (ie, CD).4 We then identified 1567 donors diagnosed with incident CD during follow-up. For each of these case donors, we selected 10 control donors (n=15 665) matched for sex, age (±5 years) and date of first blood donation (±2 years) (see table 1 for details). We …
Adjuvant hormone therapy use in early-stage breast cancer patients insured by the New York State Medicaid program.
Authors: R. L. Yung, M. J. Hassett, K. Chen, F. C. Gesten, P. R. Roohan, F. P. Boscoe, A. H. Sinclair, M. J. Schymura, D. Schrag
Journal: Journal of Clinical Oncology (2011)

6031 Background: Adjuvant hormone therapy (HRx) improves outcomes for women with hormone receptor positive (HR+) early stage breast cancer (EBC). We evaluated predictors of appropriate use of adjuvant HRx among Medicaid enrolled women with EBC. Methods: Using linked records from the New York (NY) State Cancer Registry, Medicaid and Medicare, we evaluated the frequency and predictors of HRx use among women 21-64 years old diagnosed in 2004-6 with stage I-III HR+ EBC. HRx was considered present if there was at least one prescription for tamoxifen, letrozole, exemestane, or anastrozole during the year after diagnosis. Multivariable (MV) regression models were constructed to identify factors associated with appropriate HRx. Results: Within 1 year of diagnosis, 1049/1538 = 68% of EBC patients received HRx. Factors associated with receipt of HRx included: receipt of cash assistance (a marker of lower income), earlier stage disease, dual expression of ER+ and PR+, mastectomy and receipt of radiation therapy. Notably, comorbid medical conditions, psychosis, depression, substance abuse, race/ethnicity and age were not associated with HRx. Within 18 months of diagnosis, the proportion of women with HRx increased to 80%. Conclusions: There appears to be underuse of HRx among women with HR+ EBC enrolled in the NY state Medicaid program. Some women never receive treatment and others appear to start after considerable delay suggesting opportunities for improving EBC treatment for program participants. Characteristics significant on MV analysis N % receiving HRx in 1st year Adjusted odds ratio (95% confidence interval) Total cohort 1,538 68% - Basis of Medicaid eligibility No disability, no cash assistance 476 70% 1.0 No disability, cash assistance 131 55% 0.65 (0.43–0.98) Disability, no cash assistance 156 70% 1.2 (0.8–1.8) Disability, cash assistance 775 69% 1.2 (0.9–1.6) Stage I 642 75% 1.0 II 647 67% 0.69 (0.52–0.92) III 249 53% 0.28 (0.19–0.42) Receptor status ER+/PR+ 1,191 70% 1.0 ER+/PR- 304 64% 0.75 (0.56–0.99) ER-/PR+ 43 53% 0.51 (0.26–0.99) Radiation No 912 75% 1.0 Yes 632 58% 3.2 (2.4–4.2)
Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia
Authors: Giovanni Del Poeta, Francesca Maria Rossi, Maria Ilaria Del Principe, Michele Dal Bo, Annalisa Biagi, Antonella Zucchetto, Francesco Buccisano, Pietro Bulian, Luca Maurillo, Gianfranco Catalano, Adriano Venditti, Paolo de Fabritiis, Sergio Amadori, Valter Gattei
Journal: Blood (2012)
Whole Body PET-CT In Management Of Lymphoblastic Lymphomas In Adults: Does It Have a Prognostic Impact?
Authors: Manju Sengar, Hasmukh Jain, Hari Menon, Sridhar Epari, Archi Agrawal, Venkatesh Rangarajan, Tanuja Shet, Sumeet Gujral, Siddhartha Laskar
Journal: Blood (2013)
Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).
Authors: Klaus Hollmig, Julie Stover, Giampaolo Talamo, Athanasios Fassas, Choon-Kee Lee, Elias Anaissie, Guido Tricot, Bart Barlogie
Journal: Blood (2004)
Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes
Authors: Marcella Rocchetti, Luca Sala, Lisa Dreizehnter, Lia Crotti, Daniel Sinnecker, Manuela Mura, Luna Simona Pane, Claudia Altomare, Eleonora Torre, Gaspare Mostacciuolo, Stefano Severi, Alberto Porta, Gaetano M. De Ferrari, Alfred L George, Peter J. Schwartz, Massimiliano Gnecchi, Alessandra Moretti, Antonio Zaza
Journal: Cardiovascular Research (2017)

Calmodulin (CaM) is a small protein, encoded by three genes (CALM1-3), exerting multiple Ca2+-dependent modulatory roles. A mutation (F142L) affecting only one of the six CALM alleles is associated with long QT syndrome (LQTS) characterized by recurrent cardiac arrests. This phenotypic severity is unexpected from the predicted allelic balance. In this work, the effects of heterozygous CALM1-F142L have been investigated in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) obtained from a LQTS patient carrying the F142L mutation, i.e. in the context of native allelic ratio and potential gene modifiers.Skin fibroblasts of the mutation carrier and two unrelated healthy subjects (controls) were reprogrammed to hiPSC and differentiated into hiPSC-CMs. Scanty IK1 expression, an hiPSC-CMs feature potentially biasing repolarization, was corrected by addition of simulated IK1 (Dynamic-Clamp). Abnormalities in repolarization rate-dependency (in single cells and cell aggregates), membrane currents and intracellular Ca2+ dynamics were evaluated as putative arrhythmogenic factors. CALM1-F142L prolonged repolarization, altered its rate-dependency and its response to isoproterenol. This was associated with severe impairment of Ca2+-dependent inactivation (CDI) of ICaL, resulting in augmented inward current during the plateau phase. As a result, the repolarization of mutant cells failed to adapt to high pacing rates, a finding well reproduced by using a recent hiPSC-CM action potential model. The mutation failed to affect IKs and INaL and changed If only marginally. Intracellular Ca2+ dynamics and Ca2+ store stability were not significantly modified. Mutation-induced repolarization abnormalities were reversed by verapamil.The main functional derangement in CALM1-F142L was prolonged repolarization with altered rate-dependency and sensitivity to β-adrenergic stimulation. Impaired CDI of ICaL underlined the electrical abnormality, which was sensitive to ICaL blockade. High mutation penetrance was confirmed in the presence of the native genotype, implying strong dominance of effects.
Single Immunophenotypical Evaluation of Minimal Residual Disease before Autotransplantation of Non-Cryopreserved Bone Marrow Is Insufficient for Prediction of Outcome in High Risk Adult Acute Lymphoblastic Leukemia.
Authors: Beata M. Stella-Holowiecka, Krystyna Jagoda, Aleksandra M. Holowiecka-Goral, Tomasz Czerw, Sebastian Giebel, Malgorzata Krawczyk-Kulis, Jerzy Holowiecki
Journal: Blood (2004)
MNGO-03FACTOR XIII ASSOCIATED RISK OF PULMONARY EMBOLISM DURING MENINGIOMA SURGERY
Authors: Stefan Grau, Friedrich W. Kreth, Volker Huge, Walter Rachinger, Andreas Meyer-Bender, Dominik Morhard, Peter Goehring, Maximilian I. Ruge, Roland Goldbrunner, Jörg-Christian Tonn
Journal: Neuro-Oncology (2015)

BACKGROUND: This study was conducted to evaluate the risk factors for early (within 24 hours) pulmonary embolism after meningioma surgery, focussing on the role of factor XIII. METHODS: 420 consecutive patients were enrolled in this prospective cohort study. The incidence of pulmonary embolism, activity levels and substitution of factor XIII, standard coagulation parameters, as well as surgery related parameters were monitored. RESULTS: Pulmonary embolism occurred in 33 (7.9%) cases. Patients with embolism had longer surgery (p = 0.02), a higher preoperative factor XIII activity (p 120% was 3.9 (95% CI 1.77-8.62), which increased to 6.4 (95% CI 3.00-13.7) in procedures lasting more than four hours. CONCLUSION: This is the first study demonstrating a strong impact of factor XIII activity on the incidence of pulmonary embolism during a specific surgical setting, thus underlining the complex interrelation of prophylactic measurements to reduce the rate of postoperative haemorrhage and pulmonary embolism after surgery.
The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.
Authors: Richard F. Schlenk, Konstanze Döhner, Michael Kneba, Francesco del Valle, Frank Hartmann, Heinz Kirchen, Elisabeth Koller, Katharina Götze, Jörg Th. Fischer, Marianne Habdank, Daniela Späth, Silja Groner, Andrea Corbacioglu, Axel Benner, Stefan Fröhling, Hartmut Döhner
Journal: Blood (2007)
Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients.
Authors: Tamar Tadmor, Bari Alessia, Stefano Sacchi, Luigi Marcheselli, Eliana Valentina Liardo, Irit Avivi, Noam Benyamini, Dina Attias, Samantha Pozzi, Massimo Federico, Aaron Polliack
Journal: Blood (2012)
Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.
Authors: Michael Kneidinger, Karoline V. Gleixner, Rudin Kondo, Puchit Samorapoompichit, Anja Vales, Maria T. Krauth, Matthias Mayerhofer, Alexander Gruze, Winfried F. Pickl, Khaled Greish, Alexandra Boehm, Wolfgang R. Sperr, Hiroshi Maeda, Peter Valent
Journal: Blood (2006)
Equilibrative Nucleoside Transporter-2 (ENT2) Protein Correlates with Ex-Vivo Sensitivity to Fludarabine in Chronic Lymphocytic Leukemia (CLL)-Cells.
Authors: Silvia Marce, Miriam Molina-Arcas, Neus Villamor, Isabel Huber, F. Javier Casado, Beatriz Bellosillo, Emili Montserrat, Marcal Pastor-Anglada, Dolors Colomer
Journal: Blood (2004)
Follicular Lymphoma Infiltrating CD4+CD25+GITR+ Regulatory T-Cells Are Potent Suppressors of CD3/CD28 Co-Stimulated Autologous and Allogeneic CD8+CD25− and CD4+CD25− T-Cells.
Authors: Shannon P. Hilchey, Richard B. Bankert, Lisa M. Rimsza, Steven H. Bernstein
Journal: Blood (2006)
The Safety, Tolerability and Efficacy of Deferasirox in Older Patients with Transfusional Dependent Anemia
Authors: Eleonora Arboscello, Lisette Del Corso, Jacopo Agnelli Giacchello, Enrico Balleari, Andrea Bellodi, Carmen Di Grazia, Alida Dominietto, Serena Favorini, Anna Ghiso, Martina Giovannini, Elisa Molinari, Chiara Salvetti, Vera Sicbaldi, Paolo Strada, Gianluca Ubezio, Maria Teresa Van Lint, Luana Vignolo, Riccardo Ghio
Journal: Blood (2014)
Association Between Micro-RNA and Epigenetic Modifiers DNA Methyltransferases (DNMTs), Histone Deacetylases (HDACs) in Multiple Myeloma (MM) and Monoclonal Gammmopathy with Undetermined Significance (MGUS)
Authors: Hiroshi Handa, Hikaru Hattori, Noriyuki Takahashi, Yoshiko Sasaki, Takayuki Saitoh, Yohei Osaki, Kenichi Tahara, Hiromi Koiso, Takeki Mitsui, Hiroaki Shimizu, Makiko Takizawa, Akihiko Yokohama, Norifumi Tsukamoto, Lobna Alkebsi, Yoshihisa Nojima, Hirokazu Murakami
Journal: Blood (2012)
beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects
Authors: H Lehmann, N P Nair, N S Kline
Journal: American Journal of Psychiatry (1979)

The authors conducted single- and double-blind studies of the responses of 7 chronic male schizophrenic patients to 10 mg of naloxone. BPRS ratings were made before and 6 hours after the injection; ACTH blood levels were determined before and 1 1/2 and 6 hours after injection. Statistically significant improvement of psychotic behavior occurred after 6 hours. The greatest improvement occurred in the patient who showed the most pronounced diurnal variation of ACTH levels, and there was no improvement in the patient who had no diurnal changes. Prolactin plasma levels following endorphin injections were apparently dose-dependent and peaked at approximately 30 minutes. The mean half-life of elimination of exogenous beta-endorphin was between 12 and 35 minutes. The authors theorize that positive and negative behavioral responses to naloxone depend--as possibly do many placebo responses in general--on the relative stress produced by experimental or therapeutic interventions.
Exome Sequencing of Familial MDS Reveals Novel Mutations and High Rates of False Positive Mutations in MLL3 Due to Pseudogene Effects
Authors: Timothy Geoffrey Bowler, Matthias Bartenstein, Kerry A. Morrone, Mersedeh Rohanizadegan, Rachel M. Kessel, Lauren Hooda, Ishan Datt, Orsolya Giricz, Tushar D. Bhagat, Bartlomiej P Przychodzen, Simrit Parmar, Jonathan B. Gill, Yiting Yu, Jaroslaw P. Maciejewski, Ulrich Steidl, Amit Verma
Journal: Blood (2014)
Ultrasociality and the division of cognitive labor
Authors: Nicholaus Samuel Noles, Judith Harmony Danovitch
Journal: Behavioral and Brain Sciences (2016)

Gowdy & Krall describe the development of ultrasociality in terms of economics and the division of labor. We propose that the division of cognitive labor allows humans to behave in an ultrasocial manner without the radical evolutionary changes that are experienced by other species, suggesting that species may traverse different paths to achieve ultrasociality.
Long-Term Follow-Up of Large Flat Colorectal Tumors Resected Endoscopically
Authors: S Higaki, S Hashimoto, K Harada, H Nohara, Y Saito, T Gondo, K Okita
Journal: Endoscopy (2003)

When a large flat colorectal tumor is excised by piecemeal endoscopic resection, it is not possible to obtain suitable specimens for histopathological examination to assess whether the resection has been complete. We prospectively analysed follow-up colonoscopy examinations of endoscopic polypectomy resection sites for residual lesions.A total of 24 patients with large flat colorectal tumors were treated using an endoscopic submucosal saline injection technique. The resection site was prospectively examined for residual lesions using a magnifying colonoscope, at 3, 6, 12 and 24 months postoperatively.None of the 5 patients who underwent en bloc resection exhibited residual lesions postoperatively. Of the 19 patients who underwent piecemeal resection, one died of an asthma attack and 18 were followed up. Residual lesions were detected in four of these 18 patients (three adenomas and one cancer), which were resected endoscopically. When the tumor was resected endoscopically en bloc and was judged histologically to be completely resected, residual lesions were not detected at follow-up. However, residual lesions were detected in 22.2 % of patients 3 months after initial resection when polyps were resected piecemeal. After treatment, residual lesions were detected in two patients (11.1 %) at 24 months.After piecemeal endoscopic resection for large flat colorectal tumors, it is necessary to follow-up and remove residual lesions endoscopically every 3 months until they all are removed.
A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Authors: Kim N. Chi, Sebastien J. Hotte, Susan Ellard, Joel Roger Gingerich, Anthony Michael Joshua, Christian K. Kollmannsberger, Evan Y. Yu, Martin Edwin Gleave
Journal: Journal of Clinical Oncology (2012)

121 Background: Heat Shock Protein 27 (Hsp27) is a stress-activated, multi-functional chaperone protein highly expressed in cancer that regulates cell signaling and survival pathways implicated in cancer progression. In prostate cancer models, Hsp27 complexes with androgen receptor (AR) and enhances transactivation of AR-regulated genes. OGX-427 is a 2nd generation antisense that inhibits Hsp27 expression with in vitro and in vivo efficacy. Phase I studies have demonstrated tolerability and single agent activity. Methods: Patients (pts) with CRPC, no/minimal symptoms and any prior treatment other than chemotherapy were randomized 1:1 to receive prednisone (P) 5 mg PO BID or P with OGX-427 600 mg IV x 3 loading doses followed by 1000 mg IV weekly. Primary endpoint was the proportion of pts progression free (PSAWG 2 criteria) at 12 weeks. A 2-stage MinMax design (H0 = 5%, HA &gt;20%, α=0.1, β=0.1) will enrol 32 pts total per arm and provide 70% power to detect the difference at a 0.10 1-sided significance. Secondary endpoints include PSA decline, measurable disease response, and circulating tumour cell (CTC) enumeration. Results: In the first 22 pts randomized (11 to OGX-427+P, 11 to P), baseline median age was 71 years (53-86), ECOG PS 0 or 1 in 64% and 36% of pts, median PSA 89 (6-606), metastases in bone/lymph nodes/liver or lung in 77%/64%/10%, 23% had prior treatment with P, and 91% had ≥5 CTC/7.5 ml (median 18/7.5 ml). Thus far, 82% of pts randomized to OGX-427+P have had a PSA decline (55% with ≥30% decline) and 18% a PSA increase; 40% of pts treated with P have had a PSA decline (20% with ≥30% decline), 10% no change and 50% with PSA increase. CTC conversion from ≥5 to &lt;5/7.5 ml has occurred in 60% of pts randomized to OGX-427+P and 20% of pts treated with P alone. Grade 1-2 infusion reactions (e.g., chills, diarrhea, flushing) have occurred in 45% of pts receiving OGX-427+P and 1 pt developed hemolytic uremic syndrome after week 7 probably related to OGX. Conclusions: Preliminary data provide clinical support for the role of Hsp27 in AR signalling and as a therapeutic target for prostate cancer. Enrolment on this study continues. Funded by a grant from the Terry Fox Research Institute.
Longitudinal analysis of treatment-induced genomic alterations in gliomas
Authors: E. Zeynep Erson-Omay, Octavian Henegariu, S. Bülent Omay, Akdes Serin Harmancı, Mark W. Youngblood, Ketu Mishra-Gorur, Jie Li, Koray Özduman, Geneive Carrión-Grant, Victoria E. Clark, Caner Çağlar, Mehmet Bakırcıoğlu, M. Necmettin Pamir, Viviane Tabar, Alexander O. Vortmeyer, Kaya Bilguvar, Katsuhito Yasuno, Lisa M. DeAngelis, Joachim M. Baehring, Jennifer Moliterno, Murat Günel
Journal: Genome Medicine (2017)

Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy, and chemotherapy; however, individual tumors display immense variability in their response to these approaches. Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular basis of this variability. Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences, demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical decision-making. We also analyze the Yale-Glioma cohort, composed of 110 whole exome- or whole genome-sequenced tumor-normal pairs, to assess the frequency of genomic events found in the presented case. Our longitudinal analysis revealed how the genomic profile evolved under the pressure of therapy. Specifically targeted approaches eradicated treatment-sensitive clones while enriching for resistant ones, generated due to chromothripsis, which we show to be a frequent event in GBMs based on our extended analysis of 110 gliomas in the Yale-Glioma cohort. Despite chromothripsis and the later acquired mismatch-repair deficiency, genomics-guided personalized treatment extended survival to over 5 years. Interestingly, the case displayed a favorable response to immune checkpoint inhibition after acquiring mismatch repair deficiency. Our study demonstrates the importance of longitudinal genomic profiling to adjust to the dynamic nature of treatment-induced molecular changes to improve the outcomes of precision therapies.
Inhibiting the IGF-1 Receptor Tyrosine Kinase with Picropodophillin: An In Vitro and In Vivo Study in the 5T33MM Mouse Model.
Authors: Karin Vanderkerken, Eline Menu, Thomas Stromberg, Hendrik De Raeve, Kewal Asosingh, Ben Van Camp, Helena Jernberg-Wiklund
Journal: Blood (2004)
Pulsing with Blast Cell Lysate or Blast-Derived Total RNA Reverses the Dendritic Cell-Mediated Increase in Cytotoxic Activity of Cytokine-Induced Killer Cells Against Human Allogeneic Acute Myelogenous Leukemia Cells.
Authors: Bjorn Schottker, Angela Marten, Carsten Ziske, Marcus Gorschluter, Ingo G.H. Schmidt-Wolf
Journal: Blood (2004)
Ribosomal RNA Expression In CD34+ Hematopoietic Progenitor Cells Inversely Correlates with Ribosomal DNA Methylation In Myelodysplastic Syndromes.
Authors: Aparna Raval, Daniel A Pollyea, Kunju J Shridhar, Shripa Patel, Peter L. Greenberg, Beverly S. Mitchell
Journal: Blood (2010)
The Evolution of Informed Consent for Surgery Using the Best Case/Worst Case Framework
Authors: Peter Angelos
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal